| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 有机电致发光材料和器件 | CN201811460845.3 | 2018-12-02 | CN109912619B | 2022-05-20 | 夏传军 |
| 公开了一种有机电致发光材料和器件。所述有机电致发光材料是具有苯并二噻吩或其类似结构新型化合物，可用作电致发光器件中的电荷传输层、空穴注入层、电荷产生层等。与已有的材料相比，这些新型化合物能提供优良的器件性能，例如进一步改进OLED的电压，效率和/或寿命。 | ||||||
| 2 | 改善的氨基脂质和递送核酸的方法 | CN200980149266.X | 2009-10-09 | CN102245590B | 2014-03-19 | 迈克尔·J·霍普; 肖恩·C·森普尔; 陈建新; 托马斯·D·马登; 皮埃特·R·卡利斯; 马尔科·A·丘福利尼; 芭芭拉·穆伊 |
| 本发明提供用于向细胞递送治疗剂的优良组合物和方法。具体地，这些包括新型脂质和核酸-脂质颗粒，其提供有效的核酸包封和在体内包封的核酸向细胞的有效递送。本发明的组合物是高度有效的，由此允许以相对低的剂量有效地敲低特定的靶蛋白。另外，与本领域先前已知的组合物和方法相比，本发明的组合物和方法毒性较小，并且提供较高的治疗指数。 | ||||||
| 3 | 有机电致发光材料和器件 | CN201811460845.3 | 2018-12-02 | CN109912619A | 2019-06-21 | 夏传军 |
| 公开了一种有机电致发光材料和器件。所述有机电致发光材料是具有苯并二噻吩或其类似结构新型化合物，可用作电致发光器件中的电荷传输层、空穴注入层、电荷产生层等。与已有的材料相比，这些新型化合物能提供优良的器件性能，例如进一步改进OLED的电压，效率和/或寿命。 | ||||||
| 4 | 改善的氨基脂质和递送核酸的方法 | CN200980149266.X | 2009-10-09 | CN102245590A | 2011-11-16 | 迈克尔·J·霍普; 肖恩·C·森普尔; 陈建新; 托马斯·D·马登; 皮埃特·R·卡利斯; 马尔科·A·丘福利尼; 芭芭拉·穆伊 |
| 本发明提供用于向细胞递送治疗剂的优良组合物和方法。具体地，这些包括新型脂质和核酸-脂质颗粒，其提供有效的核酸包封和在体内包封的核酸向细胞的有效递送。本发明的组合物是高度有效的，由此允许以相对低的剂量有效地敲低特定的靶蛋白。另外，与本领域先前已知的组合物和方法相比，本发明的组合物和方法毒性较小，并且提供较高的治疗指数。 | ||||||
| 5 | 改良的水溶性药物制剂 | CN00805399.5 | 2000-03-20 | CN1156461C | 2004-07-07 | D·F·埃尔科波尼; R·S·小弗拉德卡; P·R·斯泰约斯 |
| 本发明描述了一种微溶于水的结晶态药物活性剂制剂，其中活性剂被转化成它的非晶态即通常疏水性载体的固溶体形式，并在该状态下稳定。非晶态通过制剂的组分来稳定，使改良后的组合物储藏期限长。该稳定的制剂其活性剂的溶解度和生物利用度增加。活性剂溶液由其组分来稳定，防止了微溶性结晶态的活性剂从它的水溶液中重结晶和沉淀。 | ||||||
| 6 | 改良的水溶性药物制剂 | CN00805399.5 | 2000-03-20 | CN1379768A | 2002-11-13 | D·F·埃尔科波尼; R·S·小弗拉德卡; P·R·斯泰约斯 |
| 本发明描述了一种微溶于水的结晶态药物活性剂制剂,其中活性剂被转化成它的非晶态即通常疏水性载体的固溶体形式,并在该状态下稳定。非晶态通过制剂的组分来稳定,使改良后的组合物储藏期限长。该稳定的制剂其活性剂的溶解度和生物利用度增加。活性剂溶液由其组分来稳定,防止了微溶性结晶态的活性剂从它的水溶液中重结晶和沉淀。 | ||||||
| 7 | JPH01500429A - | JP50372287 | 1987-06-24 | JPH01500429A | 1989-02-16 | |
| 8 | Monocyclic nucleoside, its analogue and use | JP2002318773 | 2002-10-31 | JP2003176296A | 2003-06-24 | RAMASAMY KANDASAMY; TAM ROBERT; DEBERON ABERT |
| <P>PROBLEM TO BE SOLVED: To provide a new monocyclic L-nucleoside compound which is supposed to be useful for treating various diseases including infections, parasite invasion, neoplasms and autoimmune diseases. <P>SOLUTION: This new L-nucleoside compound represented by the general formula (I). The new compound has an immunoregulatory activity, and is expected to be useful on cytokine pattern regulations including the regulation of Th1 and Th2 reactions. <P>COPYRIGHT: (C)2003,JPO | ||||||
| 9 | Pharmaceutical formulations with improved aqueous solubility | JP2000606587 | 2000-03-20 | JP2003531099A | 2003-10-21 | エフ アーコボニ，デビッド; アール スタジオス，パメラ; エス ジュニア ブラディカ，ロナルド |
| (57)【要約】 【課題】 常態で殆ど水不溶性の結晶状の製薬上活性な薬剤の改良された水溶解度をもつ医薬製剤を提供するものである。 【解決手段】 （ａ）疎水性賦形剤を、該疎水性賦形剤が融解する温度以上の温度であり且つ溶融した疎水性賦形剤に製薬上活性な薬剤が溶解する温度に加熱し、（ｂ）製薬上活性な薬剤を溶融した賦形剤に溶解し、疎水性賦形剤中に製薬上活性な薬剤の溶融溶液を作り、（ｃ）製薬上活性な薬剤と疎水性賦形剤との溶融溶液に安定剤の安定有効量を加え、次いで（ｄ）工程（ｃ）からの溶融混合物を冷却した崩壊剤及び任意成分としての結合剤と共に３０°Ｃ以下の温度で粒状化し、疎水性賦形剤中に無定形の形態で安定した製薬上活性な薬剤の固溶体を含む粒状化粒子を形成する、各工程から製造する。 【効果】 無定形状態で製剤組成物によって安定化され、そして改良された組成物の長期貯蔵寿命を提供する。 この安定化製剤はまた活性薬剤の溶解度及び生物学的利用能を増加する。 活性薬剤の溶液はこの組成物によって安定化され、その水溶液において活性薬剤が殆ど溶解しない結晶性形態への再結晶及び沈殿を防止する。 | ||||||
| 10 | Monocyclic nucleoside, its analogues and use | JP51861298 | 1997-10-15 | JP2002503212A | 2002-01-29 | アルベルト，デベロン; タム，ロバート; ラマサミー，カンダサミー |
| (57)【要約】 一般式（Ｉ）で示される新規単環式Ｌ−ヌクレオシド化合物。 これらの化合物の態様は、感染、寄生虫の侵入、新生物および自己免疫疾患を含む種々の病気を治療するのに有用であると考えられる。 新規化合物の機構、態様に関しては、免疫調節活性が見られ、Ｔｈ１およびＴｈ２反応の調節を含むサイトカインパターンの調節において有用であると期待される。 | ||||||
| 11 | IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | PCT/US2009/060251 | 2009-10-09 | WO2010042877A1 | 2010-04-15 | HOPE, Michael, J.; SEMPLE, Sean, C.; CHEN, Jianxin; MADDEN, Thomas, D.; CULLIS, Pieter, R.; CIUFOLINI, Marco, A.; MUI, Barbara |
The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. |
||||||
| 12 | 키나아제 억제제 및 이의 용도 | KR1020197036911 | 2018-05-17 | KR1020200006125A | 2020-01-17 | |
| 13 | 키나아제 억제제 및 이의 용도 | KR1020197036911 | 2018-05-17 | KR102638151B1 | 2024-02-16 | |
| 14 | THERAPEUTIC METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING WARTS WITH TELLURIUM COMPOUNDS | PCT/IL2005000084 | 2005-01-23 | WO2005069735A3 | 2009-04-23 | SREDNI BENJAMIN; ALBECK MICHAEL |
| A novel method for treating skin and mucosal membrane ailments caused by human papilloma viruses, which utilizes tellurium-containing compounds, is disclosed. Also disclosed are pharmaceutical compositions containing tellurium-containing compounds for treating such ailments. | ||||||
| 15 | SYNERGISTIC INTERACTION OF NOTCH-1 INHIBITORS WITH GLUCOCORTICOIDS | PCT/US2008/003268 | 2008-03-13 | WO2008112249A1 | 2008-09-18 | FERRANDO, Aldolfo, A.; REAL, Pedro, J. |
The present invention relates to methods and compositions for preventing and/or treating various conditions in a patient, including for example, T-cell lymphoblastic leukemia and lymphoma as well as neurodegenerative diseases, such as for example, Alzheimer's disease. In one preferred embodiment of the invention, such methods include providing a patient with an effective amount of a combination of a NOTCH-1 inhibitor and glucocorticoid. The present invention further encompasses methods for increasing the efficacy of, and mitigating resistance to, glucocorticoids in the treatment of T-cell lymphoblastic leukemia and lymphoma, which generally include providing a patient with an effective amount of one or more NOTCH-1 inhibitors. |
||||||
| 16 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | PCT/US9718767 | 1997-10-15 | WO9816186A3 | 1998-06-11 | RAMASAMY KANDASAMY; TAM ROBERT; AVERETT DEVRON |
| Novel monocyclic L-nucleoside compounds have general formula (I). Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response. 00000 | ||||||
| 17 | FLUORINATED AROMATIC MATERIALS AND THEIR USE IN OPTOELECTRONICS | EP15196039.0 | 2010-08-20 | EP3042890A3 | 2016-10-19 | SUN, Haoran |
Fluorinated aromatic materials, their synthesis and their use in optoelectronics. In some cases, the fluorinated aromatic materials are perfluoroalkylated aromatic materials that may include perfluoropolyether substituents.
|
||||||
| 18 | FIELD EFFECT TRANSISTOR | EP10746251 | 2010-02-25 | EP2402348A4 | 2012-06-20 | KUWABARA HIROKAZU; IKEDA MASAAKI; TAKIMIYA KAZUO |
| 19 | THERAPEUTIC METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING WARTS WITH TELLURIUM COMPOUNDS | EP05703127 | 2005-01-23 | EP1715785A4 | 2009-07-22 | SREDNI BENJAMIN; ALBECK MICHAEL |
| A novel method for treating skin and mucosal membrane ailments caused by human papilloma viruses, which utilizes tellurium-containing compounds, is disclosed. Also disclosed are pharmaceutical compositions containing tellurium-containing compounds for treating such ailments. | ||||||
| 20 | NOVEL ANTI-ADHESIVE COMPOUNDS AND USES THEREOF | EP02725119 | 2002-03-12 | EP1385821A4 | 2006-03-08 | ALBERTE RANDALL S; SMITH ROBERT D |
| Compounds which exhibit anti-adhesive properties are described. The compounds may be monomers or polymers. Methods for treating receptor mediated diseases are provided using compounds of the invention. Further methods are provided for crop protection, medical devices and anti-fouling. | ||||||
